We found a significant increase in 89.3% of DCIS lesions compared to NAT in TMA1 (Fig. 1A, 1E, Supp Fig. 1C) and CD68 positive cells increased in 75% of DCIS compared to NAT and 79.8% of IDC compared to DCIS in TMA2 (Fig. 1B, 1F, Supp Table 1). The gene discussed is BRD2; the disease is ductal breast carcinoma in situ.